title: Fistula response to methotrexate in Crohn's disease: a case series.
abstract: BACKGROUND
  Controlled trials have demonstrated the efficacy of methotrexate in the induction and maintenance of remission in luminal Crohn's disease; however, its effect on fistulizing disease is unknown.
  
  
  OBJECTIVE
  To describe the response to methotrexate therapy in a series of patients with fistulizing Crohn's disease.
  
  
  METHODS
  A retrospective chart review was conducted of all patients with Crohn's disease receiving methotrexate in one practice. The response of patients with fistulizing and luminal disease was assessed using clinical and laboratory criteria. Fistula response was categorized as either complete or partial closure.
  
  
  RESULTS
  Thirty-seven courses of methotrexate therapy were given to 33 patients with luminal and/or fistulizing Crohn's disease. In 16 patients with fistulas, four (25%) had complete closure, five (31%) had partial closure and all had failed or were intolerant to 6-mercaptopurine therapy. Overall, response to methotrexate was seen in 23 of 37 (62%) treatment courses in patients with luminal and/or fistulizing Crohn's disease. Two of the 33 patients (6%) had a significant adverse event.
  
  
  CONCLUSIONS
  In this case series, 56% of patients with Crohn's fistulas on methotrexate showed a complete or partial response to therapy. Further studies are needed to confirm the role of methotrexate alone, and in combination with other therapies, for the treatment of fistulizing Crohn's disease.
authors: Division of Gastroenterology and Department of Medicine, University of California, San Francisco, CA, USA. umamah@itsa.ucsf.edu
authors: U
authors: U
authors: Mahadevan
authors: J F
authors: JF
authors: Marion
authors: D H
authors: DH
authors: Present
mesh_terms: D034861:Abdominal Wall; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D017577:Cutaneous Fistula / Q000150:complications / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007412:Intestinal Fistula / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D012002:Rectal Diseases / Q000150:complications / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000150:complications / Q000188:drug therapy; D014548:Urinary Fistula / Q000150:complications / Q000188:drug therapy; D014624:Vaginal Fistula / Q000150:complications / Q000188:drug therapy
chemical_list: D005765:Gastrointestinal Agents; D016572:Cyclosporine; D015122:Mercaptopurine